Article in Science translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
23 authors.
Sachin SharmaDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, CA 94143, USA.ORCID 0000-0001-5161-6946
Vijaya PrathigudupuDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, CA 94143, USA.ORCID 0009-0009-3070-5662
Carson CableDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, CA 94143, USA.
Lia R SerranoDepartment of Chemistry, University of Wisconsin-Madison, Madison, WI 53706, USA.ORCID 0000-0001-5662-5884
Srilaxmi NerellaDivision of Pulmonary, Critical Care, Allergy, and Sleep, Department of Medicine, University of California, San Francisco, CA 94143, USA.
Alina ChenDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, CA 94143, USA.ORCID 0009-0004-1849-6785
Ghmkin HassanCenter for Bioengineering and Tissue Regeneration, Department of Surgery, University of California, San Francisco, CA 94143, USA.ORCID 0000-0002-2725-7899
Johnathon LakinsCenter for Bioengineering and Tissue Regeneration, Department of Surgery, University of California, San Francisco, CA 94143, USA.ORCID 0000-0002-1686-5063
Carlos Lizama ValenzuelaDepartment of Pediatrics, University of California, San Francisco, CA 94143, USA.
Tatsuya TsukuiDivision of Pulmonary, Critical Care, Allergy, and Sleep, Department of Medicine, University of California, San Francisco, CA 94143, USA.ORCID 0000-0003-3100-6934
Roopa RamamoorthiInnovation Ventures, University of California, San Francisco, CA 94143, USA.ORCID 0009-0004-8472-4897
Jae-Jun KimDivision of Transplant Surgery, Department of Surgery, University of California, San Francisco, CA 94143, USA.ORCID 0000-0002-8948-4501
Holger WillenbringDivision of Transplant Surgery, Department of Surgery, University of California, San Francisco, CA 94143, USA.
Aras N MattisEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA 94143, USA.ORCID 0000-0002-5813-164X
Regan F VolkDepartment of Pharmaceutical Chemistry, Cardiovascular Research Institute, University of California, San Francisco, CA 94143, USA.ORCID 0000-0001-6748-719X
Balyn W ZaroDepartment of Pharmaceutical Chemistry, Cardiovascular Research Institute, University of California, San Francisco, CA 94143, USA.ORCID 0000-0002-8938-9889
Joshua J CoonDepartment of Chemistry, University of Wisconsin-Madison, Madison, WI 53706, USA.ORCID 0000-0002-0004-8253
Richard BeresisDepartment of Pharmaceutical Chemistry, Cardiovascular Research Institute, University of California, San Francisco, CA 94143, USA.
William F DeGradoDepartment of Pharmaceutical Chemistry, Cardiovascular Research Institute, University of California, San Francisco, CA 94143, USA.ORCID 0000-0003-4745-263X
Valerie M WeaverCenter for Bioengineering and Tissue Regeneration, Department of Surgery, University of California, San Francisco, CA 94143, USA.ORCID 0000-0003-4786-6752
Stephanie A ChristensonDivision of Pulmonary, Critical Care, Allergy, and Sleep, Department of Medicine, University of California, San Francisco, CA 94143, USA.ORCID 0000-0003-1550-2815
Hyunil JoDepartment of Pharmaceutical Chemistry, Cardiovascular Research Institute, University of California, San Francisco, CA 94143, USA.ORCID 0000-0002-4863-0779
Jennifer Y ChenDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, CA 94143, USA.ORCID 0000-0001-5187-1330
Funding
UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Institutional Training in the Genomic SciencesT32HG002760 · NHGRI · UNIVERSITY OF WISCONSIN-MADISON · PI Qiongshi Lu · 2003 to 2026
$17.7M
TR&D 2 Metabolic Labels for Ultraplexed Protein Quantification p. 453P41GM108538 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI COON, JOSHUA J · 2016 to 2025
$13.1M
Deciphering the relationship between structure, dynamics and function in helical bundle proteinsR35GM122603 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WILLIAM DEGRADO · 2017 to 2026
$7.1M
Tissue mechanics reprograms the tissue to malignancy and metastasisR35CA242447 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VALERIE MARIE WEAVER · 2020 to 2026
$6.6M
Research Training in Chemistry and Chemical BiologyT32GM145460 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason E Gestwicki · 2022 to 2026
$3.1M
Role of PRKC alpha in Extracellular Matrix RemodelingR01DK134723 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Y. Chen · 2023 to 2026
$2.5M
Targeting Acid Ceramidase for Hepatic FibrogenesisR01DK137892 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Hyunil Jo · 2024 to 2026
$1.9M
Targeting AAV vectors to cell types involved in alcohol-induced liver injuryR01AA026578 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WILLENBRING, HOLGER · 2018 to 2022
Tissue fibrosis arises from a critical imbalance between the production and breakdown of extracellular matrix (ECM) components. Whereas current strategies predominantly focus on curbing ECM production, the possibility of promoting ECM degradation to resolve fibrosis remains largely untapped. The role of hepatic stellate cells (HSCs) in ECM degradation is an intriguing area for investigation. We previously demonstrated that inhibiting acid ceramidase (aCDase) increases ceramide in HSCs to ameliorate hepatic fibrosis. Here, we uncover a key signaling pathway that promotes ECM degradation in primary human HSCs, which is dependent upon the activation of protein kinase Cα (PKCα) and the induction of matrix metalloproteinase 1 (MMP-1) through extracellular signal-regulated kinase 1/2 (ERK1/2). Genetic reduction and pharmacological inhibition with a small molecule reduced aCDase activity, leading to increased collagen degradation and hepatic fibrosis resolution in the carbon tetrachloride (CCl
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Resolving fibrosis by stimulating HSC-dependent extracellular matrix degradation. · full record | OpenQuestion